A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury. The company’s research pipeline products also comprise SB623 for chronic disease, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 to treat peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
Financial Summary
| Share Statistics | SNBOY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $490.6 | $218.1 | 38% |
|
| Shares Out (Mil) | 0.5 | 53.9 | 3% |
|
| Institutional Ownership | 5.0% | 93.1% | 5% |
|
| Float (Mil) | 56.8 | 40.9 | 49% |
|
| Beta | 0.28 | 0.95 | 16% |
|
| Avg Daily Volume (000s) | 0 | 611 | 0% |
|
| Price Change (52-week) |
na | 46.3% | na |
|
| Growth | SNBOY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | 5.1% | (10.2%) | 48% |
|
| EPS (5yr) | 11.4% | 15.7% | 49 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 56.1% | (15.7%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SNBOY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($23) | ($44) | 23% |
|
| EPS (TTM) | ($0.299) | ($1.600) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | na | ($33) | na |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $7 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | $378 | $177 | 31% |
|
| Valuation | SNBOY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.13 | na |
|
| P/E | na | 19.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SNBOY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (41.8%) | (47.2%) | 13% |
|
| ROE | (54.3%) | (54.2%) | 15% |
|
| Liabilities to Assets | 14.1% | 29.1% | 9% |
|
| F-Score | na | 3 | na |
|
SanBio Company Limited did not pass any screens on 10/14/2026.
